327,588 Shares in Eli Lilly and Company $LLY Acquired by Nykredit A S

Key Points

• Nykredit A S acquired 327,588 Eli Lilly shares worth approximately $392.9 million, making Lilly its 10th-largest portfolio holding. Institutional investors collectively own 82.53% of the stock.
• Lilly reported strong quarterly results, with earnings of $8.38 per share versus the $6.40 consensus estimate and revenue of $22.97 billion, up 47.7% year over year. Growth was driven largely by demand for its Zepbound and Mounjaro obesity and diabetes treatments.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and average price target of $1,304.86, though concerns include Lilly’s premium valuation, increasing competition, and declining U.S. prices that could pressure future growth.

Nykredit A S acquired a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 327,588 shares of the company's stock, valued at approximately $392,919,000. Eli Lilly and Company makes up about 1.2% of Nykredit A S's portfolio, making the stock its 10th biggest position.

Several other institutional investors have also added to or reduced their stakes in LLY. BlackRock Inc. lifted its stake in Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after acquiring an additional 1,046,558 shares during the period. Capital World Investors grew its stake in shares of Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company's stock worth $16,154,619,000 after acquiring an additional 61,851 shares during the period. Bank of America Corp DE bought a new stake in shares of Eli Lilly and Company in the second quarter worth approximately $13,522,666,000. Norges Bank purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $12,976,634,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Eli Lilly and Company by 1.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock valued at $8,647,153,000 after purchasing an additional 137,364 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,152.13 on Friday. Eli Lilly and Company has a 12-month low of $712.05 and a 12-month high of $1,292.65. The firm has a market capitalization of $1.08 trillion, a price-to-earnings ratio of 38.66, a price-to-earnings-growth ratio of 1.40 and a beta of 0.50. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The firm has a 50 day moving average of $1,177.63 and a 200 day moving average of $1,076.26.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analysts' expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company's revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 36.53 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, September 10th. Shareholders of record on Friday, August 14th were issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, August 14th. Eli Lilly and Company's payout ratio is currently 23.22%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Berenberg upgraded Lilly to Buy and raised its price target to $1,400 from $1,220, implying roughly 20% upside. The firm cited Lilly’s strong returns on research investment and growth opportunities in the obesity-treatment market. Eli Lilly Gets a Big Price Target Boost
• Positive Sentiment: Demand for Zepbound and Mounjaro continues to drive exceptional growth. Lilly’s second-quarter revenue increased 48% year over year, reinforcing investor expectations that its GLP-1 franchise can support earnings growth and its 2026 outlook. Can Volume Keep Covering Eli Lilly's Price Cuts?
• Positive Sentiment: Lilly is expanding its drug-discovery ecosystem. Agreements with Twist Bioscience and Ginkgo Datapoints will provide antibody and laboratory data for Lilly TuneLab’s AI/ML models, potentially improving future antibody-development capabilities. Lilly also signed a genetic-medicine agreement with QurCan and participated in Circle Pharma’s $92.5 million financing. Twist Bioscience TuneLab Agreement
• Neutral Sentiment: Analysts and investors continue to debate whether Lilly’s substantial long-term share-price gains are justified by future cash generation. The company remains a favored buy-and-hold healthcare growth stock, but expectations are already elevated. Eli Lilly Stock Could Be a Bargain
• Negative Sentiment: Pricing is becoming a growing concern. Lilly’s U.S. price declined 9% year over year, excluding rebate-estimate changes. Volume has so far offset the reduction, but investors may worry about earnings and revenue pressure if volume growth eventually slows.
• Negative Sentiment: Competition from Novo Nordisk and other obesity-drug developers, along with Lilly’s premium valuation, could limit further upside. Reports about payments to physicians to promote GLP-1 drugs may also create reputational and regulatory overhang. LLY Stock Down Around 7% in a Month

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. UBS Group set a $1,376.00 target price on shares of Eli Lilly and Company in a report on Friday, August 7th. BMO Capital Markets reiterated an "outperform" rating on shares of Eli Lilly and Company in a research note on Wednesday, September 9th. HSBC increased their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the company a "reduce" rating in a report on Thursday, September 10th. Morgan Stanley restated an "overweight" rating and issued a $1,419.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 6th. Finally, Leerink Partners lifted their price objective on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an "outperform" rating in a report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average target price of $1,304.86.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 over the last quarter. 0.14% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company's products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.